Lucence Diagnostics develops advanced ultrasensitive liquid biopsy tests that profile cancer non-invasively to achieve timely tailored treatment.
Its LiquidHALLMARK® identifies somatic variants in 15 cancer types and requires just one draw of blood, with quick turnaround in just 8 days.
Seeking Taiwanese research and clinical partners to collab;
Also welcome pharmaceutical companies and insurers in developing programmes for companion diagnostics (CDx) tests.
